Annals of Surgical Oncology

, Volume 19, Issue 5, pp 1508–1516

Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

  • Manfred Kaufmann
  • Gunter von Minckwitz
  • Elefhterios P. Mamounas
  • David Cameron
  • Lisa A. Carey
  • Massimo Cristofanilli
  • Carsten Denkert
  • Wolfgang Eiermann
  • Michael Gnant
  • Jay R. Harris
  • Thomas Karn
  • Cornelia Liedtke
  • Davide Mauri
  • Roman Rouzier
  • Eugen Ruckhaeberle
  • Vladimir Semiglazov
  • W. Fraser Symmans
  • Andrew Tutt
  • Lajos Pusztai
Breast Oncology

DOI: 10.1245/s10434-011-2108-2

Cite this article as:
Kaufmann, M., von Minckwitz, G., Mamounas, E.P. et al. Ann Surg Oncol (2012) 19: 1508. doi:10.1245/s10434-011-2108-2

Abstract

The use of neoadjuvant systemic therapy (NST) for the treatment of primary breast cancer has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s, NST was shown to substantially improve breast-conserving surgery rates and was first typically used for patients with inoperable locally advanced or inflammatory breast cancer. Investigators have since also used NST as an in vivo test for chemosensitivity by assessing pathologic complete response. Today, by using pathologic response and other biomarkers as intermediate end points, results from trials of new regimens and therapies that use NST are aimed to precede and anticipate the results from larger adjuvant trials. In 2003, a panel of representatives from various breast cancer clinical research groups was first convened in Biedenkopf to formulate recommendations on the use of NST. The obtained consensus was updated in two subsequent meetings in 2004 and 2006. The most recent conference on recommendations on the use of NST took place in 2010 and forms the basis of this report.

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Manfred Kaufmann
    • 1
  • Gunter von Minckwitz
    • 2
  • Elefhterios P. Mamounas
    • 3
  • David Cameron
    • 4
  • Lisa A. Carey
    • 5
  • Massimo Cristofanilli
    • 6
  • Carsten Denkert
    • 7
  • Wolfgang Eiermann
    • 8
  • Michael Gnant
    • 9
  • Jay R. Harris
    • 10
  • Thomas Karn
    • 1
  • Cornelia Liedtke
    • 11
  • Davide Mauri
    • 12
  • Roman Rouzier
    • 13
  • Eugen Ruckhaeberle
    • 1
  • Vladimir Semiglazov
    • 14
  • W. Fraser Symmans
    • 15
  • Andrew Tutt
    • 16
  • Lajos Pusztai
    • 17
  1. 1.Department of Gynecology and Obstetrics and Breast UnitGoethe UniversityFrankfurtGermany
  2. 2.German Breast GroupNeu IsenburgGermany
  3. 3.Aultman Cancer CenterCantonUSA
  4. 4.Edinburgh Cancer Research CenterUniversity of EdinburghEdinburghUK
  5. 5.Division of Hematology-OncologyUniversity of North CarolinaChapel HillUSA
  6. 6.Department of Medical OncologyFox Chase Cancer CenterPhiladelphiaUSA
  7. 7.Institute of PathologyUniversity Hospital CharitéBerlinGermany
  8. 8.Women’s HospitalRed Cross ClinicsMunichGermany
  9. 9.Department of SurgeryMedical University of ViennaViennaAustria
  10. 10.Department of Radiation OncologyDana-Farber Cancer Institute, Harvard Medical SchoolBostonUSA
  11. 11.Department of Gynecology and ObstetricsUniversity Hospital MuensterMuensterGermany
  12. 12.Department of Medical OncologyGeneral Hospital of LamiaLamiaGreece
  13. 13.Department of Obstetrics and GynecologyHôpital TenonParisFrance
  14. 14.N.N. Petrov Research Institute of OncologySt. PetersburgRussia
  15. 15.Department of PathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  16. 16.Breakthrough Breast Cancer Research UnitGuy’s Hospital Campus, King’s College London School of MedicineLondonUK
  17. 17.Department of Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA